Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort

Slade Decker; Shaoming Xiao; Carly Dillen; Christina M. Schumacher; Aaron M. Milstone; Matthew Frieman; Amanda K. Debes

doi:10.1093/ofid/ofad625

Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort

Slade Decker, Shaoming Xiao, Carly Dillen, Christina M. Schumacher, Aaron M. Milstone, Matthew Frieman, Amanda K. Debes

Research output: Contribution to journal › Article › peer-review

Abstract

Nirmatrelvir/ritonavir (NMV/r) is used for the treatment of coronavirus disease 2019 (COVID-19) infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the severe acute respiratory syndrome coronavirus 2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.

Original language	English (US)
Article number	ofad625
Journal	Open Forum Infectious Diseases
Volume	11
Issue number	2
DOIs	https://doi.org/10.1093/ofid/ofad625
State	Published - Feb 1 2024

Keywords

COVID-19
NMV/r
antibodies
antivirals
humoral immune response
immunology
longitudinal cohort

ASJC Scopus subject areas

Oncology
Infectious Diseases

Access to Document

10.1093/ofid/ofad625

Cite this

@article{e0f07540e79b4a71884c9ab420b2d7ad,

title = "Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort",

abstract = "Nirmatrelvir/ritonavir (NMV/r) is used for the treatment of coronavirus disease 2019 (COVID-19) infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the severe acute respiratory syndrome coronavirus 2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.",

keywords = "COVID-19, NMV/r, antibodies, antivirals, humoral immune response, immunology, longitudinal cohort",

author = "Slade Decker and Shaoming Xiao and Carly Dillen and Schumacher, {Christina M.} and Milstone, {Aaron M.} and Matthew Frieman and Debes, {Amanda K.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = feb,

day = "1",

doi = "10.1093/ofid/ofad625",

language = "English (US)",

volume = "11",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort

AU - Decker, Slade

AU - Xiao, Shaoming

AU - Dillen, Carly

AU - Schumacher, Christina M.

AU - Milstone, Aaron M.

AU - Frieman, Matthew

AU - Debes, Amanda K.

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2024/2/1

Y1 - 2024/2/1

N2 - Nirmatrelvir/ritonavir (NMV/r) is used for the treatment of coronavirus disease 2019 (COVID-19) infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the severe acute respiratory syndrome coronavirus 2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.

AB - Nirmatrelvir/ritonavir (NMV/r) is used for the treatment of coronavirus disease 2019 (COVID-19) infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the severe acute respiratory syndrome coronavirus 2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.

KW - COVID-19

KW - NMV/r

KW - antibodies

KW - antivirals

KW - humoral immune response

KW - immunology

KW - longitudinal cohort

UR - http://www.scopus.com/inward/record.url?scp=85185535280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85185535280&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofad625

DO - 10.1093/ofid/ofad625

M3 - Article

C2 - 38352152

AN - SCOPUS:85185535280

SN - 2328-8957

VL - 11

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 2

M1 - ofad625

ER -

Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this